Edward Kreps to sell common shares (NASDAQ: CFLT) — Rule 144 notice

Rhea-AI Filing Summary

Edward Kreps reports proposed sales of common stock under Rule 144. The filing lists Founders Shares: 232,500 (dated 09/27/2019) and Restricted Stock Units: 37,707 (dated 02/20/2026) as securities to be sold.

The filing also discloses recent 10b5-1 sales: 12/15/2025 — 232,500 shares for $6,997,459.50; 12/12/2025 — 506,000 shares for $15,200,240.00.

Insights

Insider Transactions Counsel

Routine Rule 144 disclosure showing past 10b5-1 sales and planned disposition of restricted and founder shares.

The filing identifies 232,500 Founders Shares (09/27/2019) and 37,707 RSUs (02/20/2026) as securities to be sold under Rule 144. Those line items serve as the basis for the proposed disposals.

The record also lists two executed 10b5-1 transactions: 12/15/2025 — 232,500 shares for $6,997,459.50 and 12/12/2025 — 506,000 shares for $15,200,240.00. Timing and cash-flow treatment are set by the trading plans and Rule 144 mechanics.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	270207	8300759.04	308661566	02/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/27/2019	Founders Shares	Issuer			232500	09/27/2019	N/A
Common	02/20/2026	Restricted Stock Units	Issuer			37707	02/20/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for EDWARD KREPS 899 W. EVELYN AVENUE MOUNTAIN VIEW CA 94041	Common	12/15/2025	232500	6997459.50
EDWARD KREPS 899 W. EVELYN AVENUE MOUNTAIN VIEW CA 94041	Common	12/12/2025	506000	15200240.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Edward Kreps disclose in the Form 144 for CFLT?

He disclosed proposed sales of common stock under Rule 144, listing 232,500 Founders Shares and 37,707 Restricted Stock Units. The filing also reports two recent 10b5-1 sales: 232,500 shares on 12/15/2025 and 506,000 shares on 12/12/2025.

How many shares did Edward Kreps sell under 10b5-1 in December 2025?

The filing reports two 10b5-1 transactions totaling 738,500 shares in December 2025. Those trades were 232,500 shares on 12/15/2025 and 506,000 shares on 12/12/2025, with proceeds shown in the filing.

What proceeds were reported for the December 2025 sales by Edward Kreps?

The filing shows proceeds of $6,997,459.50 for the 232,500-share sale on 12/15/2025 and $15,200,240.00 for the 506,000-share sale on 12/12/2025. Those amounts appear in the transaction entries.

Which securities does the Form 144 list as proposed for sale?

The Form 144 lists two classes: Founders Shares totaling 232,500 (dated 09/27/2019) and Restricted Stock Units totaling 37,707 (dated 02/20/2026). Those are identified as the securities to be sold.

Does the Form 144 show whether proceeds go to the issuer or the seller?

The filing entries show execution amounts for sales by Edward Kreps and reflect cash received by the selling holder. The document lists sale proceeds for each 10b5-1 transaction; further cash-flow allocation details are governed by the trading plan and not expanded in the excerpt.